Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + fruquintinib + sodium propionate for late-line metastatic colorectal cancer (phase II)
ChiCTR2500112349Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Nov 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, fruquintinib and sodium propionate in colorectal cancer (CRC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Objective response rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
camrelizumabfruquintinibsodium propionate
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500112349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112349.